A recent RCT indicates that fluvoxamine, an SSRI, sigma-1 receptor (S1R) agonist, and FIASMA may prevent clinical deterioration in outpatients with acute COVID-19 compared to placebo (Lenze et al., 2020). This evidence concerns the gene TMBIM4 and COVID-19.